All posts

Bombardier is still a gamble, this fund manager says

Michael Decter

Bombardier’s (Bombardier Inc. Stock Quote, Chart, News: TSX:BBD.B) fortunes may have improved as of late, but don’t expect unlimited growth from the stock, says Michael Decter of LDIC Inc., who argues that the aerospace and transport company remains an investment gamble.

These days, Bombardier’s share price certainly looks better than it did a couple of years ago, when it bottomed out at $0.72 in February of 2016. Now nipping at $5.00, the stock is prompting investors to wonder how much higher can it go.

Maybe not so much more, says Decter, who cautions that the jury is out on the company’s C Series deal with Airbus, which will see the European plane maker take over production of Bombardier’s C Series jetliner, starting July 1.

“We bought [Bombardier stock] a few times and lost our nerve when it did a swan dive. I’ve started to look at it over the last few weeks and I’m starting to see analysts with $6.00 targets on it,” Decter told BNN Bloomberg Monday.

“There are some big, big moving pieces,” says Decter. “One presumes that Airbus knows how to make planes and that they’ll bring some large plane experience to bear, which should be good. How much juice is left in that deal for Bombardier is hard to tell. It’s a great plane but is it a great business?”

Last week, Bombardier lowered its revenue forecast for 2018 even as it said C Series deliveries are expected to double this year. News also broke that Bombardier is launching two new large-cabin business-class planes, the Global 5500 and the Global 6500 aircrafts, as part of the company’s intended pivot towards luxury aircraft and trains.

“I’m cautious,” says Decter. “If I had an average price of $2.50 a share, I would probably start trimming it gently above $5.00 and heavily if it gets above $6.00. I wouldn’t sell it all, but I would take some profits.”

Tagged with: bbd.b
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

5N Plus just delivered an “exceptional” quarter, this analyst says

5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP) blew past expectations in the first quarter of 2025,… [Read More]

13 hours ago

Kinaxis is still undervalued, ATB Capital says

Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials TSXV:KXS) delivered first-quarter results that met expectations, with record adjusted EBITDA and… [Read More]

13 hours ago

Spectral Medical is “fundamentally undervalued”, Paradigm says

Paradigm Capital analyst Scott McAuley is maintaining a "Buy" rating and $2.30 target on Spectral Medical (Spectral Medical Stock Quote,… [Read More]

17 hours ago

Is Ballard Power a buy?

Ballard Power’s (Ballard Power Stock Quote, Chart, News, Analysts, Financials NASDAQ:BLDP) disappointing Q1 2025 results prompted Roth Capital Partners analyst… [Read More]

18 hours ago

Propel Holdings deserves a higher P/E multiple, Ventum says

Rob Goff of Ventum Capital Markets maintained a "Buy" rating and $45.00 price target on Propel Holdings (Propel Holdings Stock… [Read More]

19 hours ago

Thinkific Labs: this analyst just chopped his price target

ATB Capital Markets is lowering its expectations for Thinkific Labs (Thinkific Labs Stock Quote, Chart, News, Analysts, Financials TSXV:THNC), with… [Read More]

1 day ago